First CAR T-cell trial for myeloma a success for Andrew
Andrew was the first person in Western Australia to have the life-changing therapy.
- Clinical trials
- Myeloma
- Treatments and side-effects
Andrew was the first person in Western Australia to have the life-changing therapy.
In a first-ever Australian-French collaboration, an exciting new clinical trial, due to open before Christmas, will give Australians with relapsed or refractory AL amyloidosis access to a new drug combination.
Dr Piers Blombery explains the basics of molecular testing which informs the treatment of blood cancer.
The Leukaemia Foundation provided consumer comments to the Pharmaceutical Benefits Advisory Committee (PBAC) in relation to Otsuka Australia Pharmaceutical’s resubmission for decitabine and cedazuridine (Inqovi®) for high-risk MDS and CMML.
Julian Lindsay’s goal is to set up an international study aimed at improving survival and quality of life through drug optimisation.
Associate Professor Michael Dickinson says CAR T-cell therapy is a 'revolutionary step forward'.
These two myeloma drugs were not recommended for listing on the PBS.
Two clinical trials will open later this year for newly diagnosed patients with AL amyloidosis with moderate to severe cardiac disease.
The drug has received a positive recommendation for PBS listing.